Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

References

• Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens X M, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A, Witzig T E, Lust J A, Lacy M Q, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens X M, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893
   PubMed Web of Science ®Google Scholar
• Knudsen L M, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma – a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212
   PubMed Web of Science ®Google Scholar
• Knudsen L M, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181
   PubMed Web of Science ®Google Scholar
• Sakhuja V, Jha V, Varma S, Joshi K, Gupta K L, Sud K, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000; 22: 465–477
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Voorhees P M, Garcia R A, Hall M D, Kudrik F J, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065
   PubMed Web of Science ®Google Scholar
• Terpos E, Anagnostopoulos A, Heath D, Kastritis E, Christoulas D, Anagnostopoulos N, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of dickkopf-1, RANKL, MIP-1α and angiogenic cytokines. Blood (suppl.) 2006; 108, Abstract 3541
   Google Scholar
• Palumbo A, Ambrosini M T, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Italian multiple myeloma network, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767–2772
   PubMed Web of Science ®Google Scholar
• Mateos M V, Hernández J M, Hernández M T, Gutiérrez N C, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase1/2study. Blood 2006; 108: 2165–2172
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa A M, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505
   PubMed Web of Science ®Google Scholar
• Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J R, Singhal S, Alexanian R, Srkalovic G, et al. SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103(6)1195–1200
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Kaufman J L, Mehta J, Richardson P G, Miller K C, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109(6)2604–2606
   PubMed Web of Science ®Google Scholar
• Onitilo A A, Engle J, Olatosi B, Fagbemi S. Community experience with bortezomib in patients with multiple myeloma. Am J Hematol 2007; 82: 637–639
   PubMed Web of Science ®Google Scholar
• Malani A K, Gupta V, Rangineni R. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol 2006; 116(4)255–258
   PubMed Web of Science ®Google Scholar
• Nozza A, Siracusano L, Armando S. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther 2006; 28(6)953–959
   PubMed Web of Science ®Google Scholar
• Ludwig H, Drach J, Graf H, Lang A, Meran J G. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411–1414
   PubMed Web of Science ®Google Scholar
• Mallick N P, Olujohungbe A, Drayson M T. Renal impairment in myeloma: time for a reappraisal?. Nephrol Dial Translant 1998; 13(Suppl 7)30–32
   PubMed Web of Science ®Google Scholar